Good MorningEquity markets were able to claw their way higher on Wednesday despite a hot read on inflation. The August CPI came in hotter than expected at the headline and core levels due to the rise of oil prices and threatens to push the Fed into another interest rate hike. The S&P 500 moved up less than 0.25% on the news, but the fact gains were made shows the market still does not believe inflation remains a problem.
The market seems to be heading into a bull trap. The S&P 500 is in rally mode despite the rising chance for additional interest rate hikes, and it is seriously mispricing the odds. As it is, the market has yet to price in another hike, and there could be more than 1 on the way. The price of WTI is up another 2.5% so far in September, the cause of hot inflation, and it is likely to continue rising. The next FOMC policy announcement is 1 week away and poses a significant threat to bullish traders. Featured: Do Not Buy Another AI Stock Before Seeing This (Ad) 
|
Technology | |
AI is hot right now and driving outsized expectations for many stocks today. One way to tell which companies have the best chances of success is to see which ones the institutions are buying. Institutional buying is significant and should be watched for many reasons. Most importantly, they have th... Read the Full Story |
|
From Our Partners | | MindWalk Holdings (NASDAQ: HYFT) is applying AI to drug discovery, and its customer base already includes 19 of the top 20 global pharmaceutical companies.
The company's HYFT technology maps roughly 660 million biological patterns and 25 billion relationships. Q1 fiscal 2027 revenue hit $3.8 million, with gross margin improving to 59 percent in its fifth consecutive quarter of year-over-year growth.
A new OpenFold3 deployment delivered about 5x faster antibody-antigen inference, and a $30 million revolving credit line, free of warrants or equity conversion, adds fuel for expansion. | | Take a closer look at HYFT before AI reshapes drug discovery. |
|
Consumer Discretionary | |
With Tesla Inc (NASDAQ: TSLA) shares having already rallied close to 200% this year, many investors will understandably be wary about chasing the bid. It’s always nice to feel like you’re getting shares at a discount whenever you decide to buy, but unless you’re one of the most a... Read the Full Story |
|
Energy | |
Based out of Canada, Enbridge Inc. (NYSE: ENB) operates the world's longest crude oil and liquids transportation system, totaling 17,809 miles of active pipeline. While it also has core businesses in the natural gas pipelines, gas utilities and storage and renewable energy segment, it still collec... Read the Full Story |
|
From Our Partners | | Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal.
Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30. | | See Jeff Brown's full analysis on Musk's new AI project |
|
Real Estate | |
Are you a REIT investor looking for diversification in your passive income streams? REITs are terrific vehicles for gaining exposure to the real estate market without going through the hassle of purchasing property. They're also imperfect assets with certain risks. A REIT alternative can mitigate ... Read the Full Story |
|
Consumer Staples | |
Kroger (NYSE: KR) is no exciting stock, but that is the point. Kroger isn’t an exciting stock, but it is a blue-chip player in consumer staples; it has solid revenue and earnings, sustainable cash flow, and pays a healthy dividend. To put its non-exciting quality into better perspective, Kro... Read the Full Story |
|
From Our Partners | | Forget Nvidia, Google, Amazon, and Microsoft. Jeff Brown says the next major AI opportunity has nothing to do with AI stocks at all.
Some of these AI assets have posted gains of 200%, 318%, and even 467% in 30 days or less, far outpacing Sandisk, 2026's top-performing AI stock, which rose just 10% in the same stretch.
Brown is highlighting five AI plays he believes carry even more upside potential, plus a free bonus pick. | | Click here to see the five AI plays and free bonus pick |
|
Consumer Staples | |
Snacks and cleaning supplies aren’t the only thing on sale at Dollar General Corporation (NYSE:DG).
Last week, shares of the discount retailer fell to their lowest level since May 2019 following a dreadful second quarter earnings report. Like a bottle of generic bleach, the move erased all ... Read the Full Story |
|
Energy | |
Shell plc (NYSE: SHEL) recently cleared price resistance above $63.69, trending higher in heavier-than-normal volume as the broader energy sector moves higher.
While the recent price move is encouraging, the dividend is also an attractive feature of Shell’s stock.
MarketBeat’s Shell... Read the Full Story |
|
Technology | |
Having easily outpaced the S&P 500 all year, Apple Inc (NASDAQ: AAPL) shares are suddenly finding themselves playing catchup against the benchmark index. Since hitting an all-time high at the end of July they’ve become noticeably cooler, and the bulls will be getting nervous. The stock i... Read the Full Story |
|
Technology | |
What goes down must come up. This has certainly been the mantra for many U.S. stocks in 2023. The most prominent example is the technology sector. Thanks to the ceremonious arrival of artificial intelligence (AI), tech stocks are getting bid up like it's 1999. As the classic Prince hit goes, it ma... Read the Full Story |
|
Real Estate | |
The real estate market in the United States is undergoing a tantrum, as neither builders nor would-be buyers are happy with how mortgage rates are behaving today. Shares of Realty Income (NYSE: O) have declined by 14.7% during the past two months... Why?
As the FED seeks to combat the wild inflat... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey. | | View Today's Stock Pick |
|
